Mammalian Cell Banking Market

Mammalian Cell Banking Market Outlook (2024 to 2034)

The mammalian cell banking market size is on track to reach US$ 499.7 million in 2024. The market is poised for rapid growth, with an extraordinary compound annual growth rate (CAGR) of 14.0% projected through 2034. This expansion is anticipated to elevate the market to a substantial valuation of US$ 1,845.6 million by 2034.

Key Mammalian Cell Banking Market Growth Factors

• A significant factor supporting the market expansion is the rising demand for biopharmaceuticals. Reliability and scalability in mammalian cell lines for manufacturing are critical as the pharmaceutical industry shifts toward biologics. Biologics' versatility and effectiveness in treating a wide range of illnesses are driving this development.
• The market is also growing due to the increased prevalence of chronic illnesses. Research and development on cell-based therapeutics is increasing as an outcome of changing lifestyles and an aging population that is driving an increased requirement for specialized solutions.
• Constant improvements in cell culture methods and biotechnology also contribute to the market's expansion. Cell banking procedures are becoming more productive and efficient owing to technological advancements, which also make them less expensive. This covers both the development of advanced cryopreservation techniques as well as the enhancement of cell culture parameters.

Report Attributes	Details
Estimated Market Value (2024E)	US$ 499.7 million
Forecasted Market Value (2034F)	US$ 1,845.6 million
Market Growth Rate (2024 to 2034)	14.0% CAGR
CHO Cell Type Segment Growth Rate (2024 to 2034)	14.6%
SEP Technology Segment Growth Rate (2024 to 2034)	14.5%
North America Market Share (2024)	42.9%
East Asia Market Share (2024)	13.9%
Key Companies Profiled	Eurofins DiscoverX Corporation Merck KGaA Sartorius Stedim BioOutsource Limited. Charles River Laboratories Altogen Labs Abzena Ltd. Northway Biotechpharma Lonza Group Ltd. VIRUSURE Selexis SA Takara Bio Inc.

What are the Key Factors Stimulating the Mammalian Cell Banking Market Growth?

Mammalian Cell Banking Culture is Taking Center Stage in Oncology Advancements

The market is growing predominantly owing to research investigations on cancer. Mammalian cell culture is a key component of research in oncology because of the particular susceptibility of cancer cells to in vitro culture. A steady supply of biological material is provided by cell lines, which is essential for scientific research. For example, in November 2018, Cancer Research United Kingdom and the Department of Biotechnology (DBT) confirmed that they had signed a Memorandum of Understanding (MoU) to form a cooperation for the India-United Kingdom Cancer Research Initiative. A five-year India-United Kingdom cancer research program, with an emphasis on finding cost-effective cancer medicines, was carried out in collaboration between the Department of Biotechnology, Cancer Research United Kingdom, and the Ministry of Science and Technology, India.

Government Initiatives are Transforming Mammalian Cell Banking Landscape

The industry is also expanding due to initiatives and assistance from regulatory bodies. Mammalian cell banking market trends indicate a growing emphasis on biopharmaceutical advancements. Governments and regulatory agencies are putting rules in place to expedite the approval procedures for cell-based medicines as they realize the value of biopharmaceuticals. The regulatory framework that supports research and development expenditures creates an atmosphere that is favorable for the growth of mammalian cell banking. With the intention of offering a global resource for the storage, characterization, and delivery of ethically authorized, quality-controlled stem cell lines for research and, eventually, therapy, the first stem cell bank in the world opened its doors in the United Kingdom. The government is attempting to achieve clinical translation of sophisticated stem cell therapy and has made significant investments in stem cell research. There is also a growing market for firms providing services for mammalian cell banks as a result of increased financing for cancer research by government bodies in the South Asia region.

Technological Breakthroughs are Propelling the Mammalian Cell Banking Market to New Heights

Mammalian cell banking market forecast reveals a promising route, predicting sustained growth driven by advancements in cell-based therapies. The evolution of cryopreservation techniques stands out as a key contributor to this growth. From the first successful cryopreservation of cells, these methods have undergone substantial improvements. Particularly, recent developments have focused on enhancing cryopreservation media. Beyond the traditional DMSO supplementation, the inclusion of additional components has become common to create a more intracellular-like environment. It is essential for maintaining cell integrity during cryopreservation. A noteworthy aspect of this progress involves the introduction of new-generation additives. By significantly reducing caspase activity, minimizing membrane permeability, and increasing membrane potential, these additives play a crucial role in reducing overall cell death induced by cryopreservation stresses. This, in turn, enhances the post-thaw performance survival rate, contributing to the overall expansion of the mammalian cell banking market.

Which Factors Pose Challenges to the Development of the Mammalian Cell Banking Industry?

Companies Struggle with Stringent Regulations in Cell Banking

While the mammalian cell banking market exhibits significant potential, it is not immune to certain challenges and restraints that can impact its growth trajectory. One notable restraint is the stringent regulatory requirements governing cell banking procedures. Companies in this industry are susceptible to challenges due to the complicated and unpredictable nature of these regulations. This necessitates a significant financial investment in compliance initiatives. A careful strategy is necessary for dealing with the regulatory environment, which might impede the rate of market expansion overall.

Shortage of Skilled Professionals Hampers Industry Advancements

Professionals with advanced skills can create new information in their industry, which can lead to innovation and progress in research and development. However, there is an absence of experienced professionals working on developmental and research projects. Some of the primary causes of the shortage of qualified professionals include low pay rates, challenging employment opportunities, and inadequate education and training in laboratories. To handle cell line culture, specialized laboratory training courses are required. The market growth is likely to be impeded throughout the forecast period owing to the expensive nature of these courses for individuals.

Fresh Biotech Firms Face Funding Hurdles in Cell Banking Infrastructure

High upfront costs associated with establishing and maintaining cell banks are another crucial factor that is expected to hinder market growth. The infrastructure required for cell banking, including specialized facilities and equipment, demands a considerable financial commitment. Small and emerging biotech firms, in particular, may find it challenging to allocate the necessary funds for such investments. This could potentially limit their participation in the market and ultimately hinder innovation.

Country-wise Insights

The North America mammalian cell banking market is gearing up for remarkable growth, foreseeing an impressive CAGR of 14.2% through 2034. The region is witnessing a surge in demand for cell banking services, driven by advancements in biotechnology and the growing need for reliable cell lines in research and development. In 2024, the United States is set to take the lead in the mammalian cell banking industry, boasting an estimated market share of 88.4%.

The mammalian cell banking market in East Asia is poised for substantial advancement, targeting a 17.5% CAGR until 2034. As the region embraces pioneering biotechnologies, the adoption of mammalian cell banking solutions has become paramount. In this region, China is likely to take the spotlight as a key player in the mammalian cell banking industry, holding a substantial market share of 59.6% in 2024.

What Aspects Contribute to the United States' Domination in the Mammalian Cell Banking Industry?

Mammalian Cell Banking Gains Momentum in the United States amidst Rise in Cancer Studies

The United States mammalian cell banking market is on the rise, given the spreading out of cancer research. The market expansion in recent years has been propelled by collaborations with NCI-designated Cancer Centers. Comprising 72 cancer research institutions, these centers, backed by the National Cancer Institute (NCI), play a central role in advancing cancer research across the country. The integration of NCI-funded cancer research into the expanding landscape of mammalian cell banking underscores a comprehensive approach to medical advancements.

Attributes	Details
United States Market Size (2024E)	US$ 189.6 million
United States Market Size (2034F)	US$ 719.1 million
United States Market CAGR (2024 to 2034)	14.3%

The surge in demand for mammalian cell banking is also fueled by the growing interest in biopharmaceuticals and regenerative medicine. In September 2022, the United States disclosed more than US$ 2 billion in monetary support for the National Biotechnology and Biomanufacturing Initiative, along with additional funding and resources. The Department of Health and Human Services additionally confirmed that it is going to allocate US$ 40 million to the advancement of biomanufacturing as a means of producing antibiotics, active pharmaceutical ingredients (APIs), and critical precursor materials required for the production of life-saving drugs. Mammalian cell banks are crucial in preserving cell lines for research and production purposes.

What Factors Back to China's Status as a Booming Market for Mammalian Cell Banking Providers?

China's Openness to Healthcare Innovation Creates Opportunities for Cell Banking Companies

The increasing demand for specialized cell culture services significantly influences the mammalian cell banking market in China. As researchers lean towards customized solutions, there is a notable shift in the preferences within the market. Cell banking companies have the opportunity to build a strong presence in China owing to the country's openness to new developments in healthcare technology. Preserving mammalian cells for therapeutic applications becomes increasingly crucial as the country makes more investments in research and development.

Attributes	Details
China Market Size (2024E)	US$ 41 million
China Market Size (2034F)	US$ 217 million
China Market CAGR (2024 to 2034)	18.0%

Providers offering customized cell banking services are gaining prominence in China over those relying solely on catalog sales. The impact is two-fold: Firstly, the demand for mammalian cell banking services that can accommodate specific project needs is on the rise. This drives providers to enhance their capabilities and offerings in this segment. In addition, the emphasis on efficient distribution networks ensures that these specialized services reach customers promptly from the manufacturing plants.

Category-wise Insights

In 2024, the CHO cell type segment is projected to be at the forefront, claiming a substantial 62.8% market share. On the other hand, the SEP technology segment is set to assert its dominance in the mammalian cell banking industry, commanding a notable 72.5% market share in 2024.

What Factors Contribute to the Preference for CHO Cell Type?

CHO Cells Revolutionize Bioprocessing, Steer Mammalian Cell Banking Industry Dominance

The CHO cell type segment is estimated to hold 66.3% of the mammalian cell banking market share by 2034. The adoption of CHO cell type is projected to rise at a CAGR of 14.6% through 2034. In the field of biologics development, Chinese Hamster Ovary (CHO) cells are the go-to choice. Their popularity stems from their low chromosome count and their significance in genetic studies. Recent advancements in bioprocessing techniques have enabled CHO cells to express high-quality proteins. It facilitates the production of recombinant proteins and monoclonal antibodies. The versatility of CHO cells extends to their use in the commercial manufacturing of therapeutic proteins and various biological and medical research, including cancer studies. With these notable advantages, CHO cells currently claim the maximum market share among cell types.

Why does SEP Technology Primarily Contribute to the Expansion of in Mammalian Cell Banking Market?

SEP Technology Emerges as Mammalian Cell Banking Leader as Stable Expression Platforms Lead the Charge

The SEP technology segment is likely to grip 75.8% of the mammalian cell banking market share by 2034. The adoption of SEP technology is anticipated to rise at a CAGR of 14.5% through 2034. This technology is widely utilized in the biopharmaceutical industry. It offers crucial advantages for early-stage manufacturers seeking financial and commercial flexibility. Ownership of cell lines, potential IP complications, royalty payments, and licensing issues may limit alternatives for those utilizing SEP. While transient technology allows for quick production of various proteins in small quantities, the significance of stable cell lines becomes apparent when aiming to produce larger material quantities. Stable expression platform technologies, often employing auxotrophic selection or epigenetic engineering, contribute to the positive factors that position SEP as the market leader.

Competitive Landscape

The key players in the mammalian cell banking market include Eurofins DiscoverX Corporation, Merck KGaA, Sartorius Stedim BioOutsource Limited., Charles River Laboratories, Altogen Labs, Abzena Ltd., Northway Biotechpharma, Lonza Group Ltd., VIRUSURE, Selexis SA, and Takara Bio Inc.

Various firms operating in the growing mammalian cell banking market create a robust competitive environment. Well-known pioneers in the field continuously reinvent their cell preservation techniques, establishing standards for both scalability and quality. New players disrupt the market with innovative technology and new points of view. Research and development endeavors are bolstered by the widespread presence of collaboration and partnerships in the market. Regulatory compliance continues to be central to the competitive advantage. The industry is characterized by a dynamic mix of experienced players and aspirational entrants, with flexibility and creativity driving growth as the demand for mammalian cell banking increases.

Recent Developments

In August 2019, Sartorius Stedim Biotech (SSB) revealed its latest offerings in August 2019 for producing mammalian cell banks in accordance with GMP guidelines. The production of GMP master and working cell banks (MCB/WCB) is one of the new services offered. The facility employs technology that permits closed-system manufacture of GMP-compliant cells and is specialized to the production of mammalian suspension cell lines.

In March 2021, the acquisition of Beacon Discovery, Inc. was made public by Eurofins DiscoverX Corporation. The purchase of Beacon Discovery advances Eurofins' goal of acting as the pharmaceutical industry's go-to partner by providing experience and a proven track record in advancing the development of innovative treatments and drug discovery.

Segmentation of Mammalian Cell Banking Market Analysis

• By Cell Type:

  • CHO
  • BHK
  • NS0
  • YB2/0 & P2/0
  • HEK293 & Derivatives
  • HELA

• By Technology:

  • TEP
  • IEP
  • SEP

• By Application:

  • MCB
  • WCB
  • EoP
  • R&D CB

• By End User:

  • Academic & Research Institute
  • Biopharmaceutical Companies
  • CROs

• By Region:

  • North America
  • Latin America
  • East Asia
  • South Asia and Pacific
  • Western Europe
  • Eastern Europe
  • Middle East and Africa